REVENUE RECOGNITION Revenue Recognition (Notes)

9 Months Ended

Sep. 30, 2020

Revenue Recognition [Abstract]

Revenue from Contract with Customer [Text Block]

REVENUE

The following table summarizes the disaggregation of revenue by nature:

	Three Months Ended September 30,				Nine Months Ended September 30,
Dollars in Millions	2020		2019		2020		2019
Net product sales	$	10,197	$	5,768	$	30,555	$	17,512
Alliance revenues	184		143		452		418
Other revenues	159		96		443		270
Total Revenues	$	10,540	$	6,007	$	31,450	$	18,200

The following table summarizes GTN adjustments:

	Three Months Ended September 30,				Nine Months Ended September 30,
Dollars in Millions	2020		2019		2020		2019
Gross product sales	$	15,211	$	8,884	$	43,685	$	25,697
GTN adjustments(a)
Charge-backs and cash discounts	(1,440)		(927)		(4,072)		(2,591)
Medicaid and Medicare rebates	(2,146)		(1,362)		(5,126)		(3,252)
Other rebates, returns, discounts and adjustments	(1,428)		(827)		(3,932)		(2,342)
Total GTN adjustments	(5,014)		(3,116)		(13,130)		(8,185)
Net product sales	$	10,197	$	5,768	$	30,555	$	17,512

(a)    Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $(25) million and $91 million for the three and nine months ended September 30, 2020 and $12 million and $139 million for the three and nine months ended September 30, 2019, respectively.

The following table summarizes the disaggregation of revenue by product and region:

	Three Months Ended September 30,				Nine Months Ended September 30,
Dollars in Millions	2020		2019		2020		2019
Prioritized Brands
Revlimid	$	3,027	$	—	$	8,826	$	—
Eliquis	2,095		1,928		6,899		5,895
Opdivo	1,780		1,817		5,199		5,441
Orencia	826		767		2,290		2,185
Pomalyst/Imnovid	777		—		2,235		—
Sprycel	544		558		1,576		1,561
Yervoy	446		353		1,211		1,104
Abraxane	342		—		950		—
Empliciti	96		89		290		263
Reblozyl	96		—		159		—
Inrebic	13		—		40		—
Zeposia	2		—		3		—
Onureg	3		—		3		—
Established Brands
Baraclude	100		145		343		433
Vidaza	106		—		390		—
Other Brands(a)	287		350		1,036		1,318
Total Revenues	$	10,540	$	6,007	$	31,450	$	18,200
United States	$	6,542	$	3,472	$	19,795	$	10,588
Europe	2,453		1,445		7,156		4,416
Rest of the World	1,361		976		4,030		2,838
Other(b)	184		114		469		358
Total Revenues	$	10,540	$	6,007	$	31,450	$	18,200

(a)    Includes BMS and Celgene products in 2020.

(b)    Other revenues include royalties and alliance-related revenues for products not sold by BMS’s regional commercial organizations.

Revenue recognized from performance obligations satisfied in prior periods was $32 million and $260 million for the three and nine months ended September 30, 2020 and $78 million and $341 million for the three and nine months ended September 30, 2019, respectively, consisting primarily of royalties for out-licensing arrangements and revised estimates for GTN adjustments related to prior period sales. Contract assets were not material at September 30, 2020 and December 31, 2019.